Abstract
Compared with the increasing and widespread bacterial resistance to clinical medicines and the urgent need for cures of intractable diseases, there is a dramatic decline in the numbers of drugs reaching the market or clinical trials. Accordingly, it has become imperative to discover more rational and efficient strategies to design and develop novel drugs. Structure-based drug design/discovery (SBDD) is one of the computer-aided methods, by which novel drugs are designed or discovered based on the knowledge of 3D structures of the relevant specific targets. During the past few decades, the great potentials and success of SBDD have been seen in the field of drug discovery. In this review, we present an overview of the key mechanisms of SBDD, the frequently used computer programs in SBDD and the reported successful cases. Finally, several typical design processes of lead components from SBDD are also highlighted in detail, such as the discovery of inhibitors of G protein-coupled receptors (GPCRs), antibacterial drugs, and anti-cancer drugs.
Keywords: Structure-based drug design, Virtual screening, de novo design, Inhibitors of GPCRs, Antibacterial drugs, Anticancer drugs.
Current Topics in Medicinal Chemistry
Title:Advances in Computational Structure-Based Drug Design and Application in Drug Discovery
Volume: 16 Issue: 9
Author(s): Tao Wang, Mian-Bin Wu, Ri-Hao Zhang, Zheng-Jie Chen, Chen Hua, Jian-Ping Lin and Li-Rong Yang
Affiliation:
Keywords: Structure-based drug design, Virtual screening, de novo design, Inhibitors of GPCRs, Antibacterial drugs, Anticancer drugs.
Abstract: Compared with the increasing and widespread bacterial resistance to clinical medicines and the urgent need for cures of intractable diseases, there is a dramatic decline in the numbers of drugs reaching the market or clinical trials. Accordingly, it has become imperative to discover more rational and efficient strategies to design and develop novel drugs. Structure-based drug design/discovery (SBDD) is one of the computer-aided methods, by which novel drugs are designed or discovered based on the knowledge of 3D structures of the relevant specific targets. During the past few decades, the great potentials and success of SBDD have been seen in the field of drug discovery. In this review, we present an overview of the key mechanisms of SBDD, the frequently used computer programs in SBDD and the reported successful cases. Finally, several typical design processes of lead components from SBDD are also highlighted in detail, such as the discovery of inhibitors of G protein-coupled receptors (GPCRs), antibacterial drugs, and anti-cancer drugs.
Export Options
About this article
Cite this article as:
Wang Tao, Wu Mian-Bin, Zhang Ri-Hao, Chen Zheng-Jie, Hua Chen, Lin Jian-Ping and Yang Li-Rong, Advances in Computational Structure-Based Drug Design and Application in Drug Discovery, Current Topics in Medicinal Chemistry 2016; 16 (9) . https://dx.doi.org/10.2174/1568026615666150825142002
DOI https://dx.doi.org/10.2174/1568026615666150825142002 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection and HCV Extrahepatic Manifestations
Current Drug Targets Development of DNA Topoisomerase II-Mediated Anticancer Agents, 3-(9- Acridinylamino)-5-hydroxymethylanilines (AHMAs) and Related Compounds
Current Medicinal Chemistry Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders
Current Drug Targets - Infectious Disorders Evaluation of the Ability of an Organic Derivative of Ruthenium(II) to Reinforce the Cytotoxicity of Fast Neutron Against Malignant Cells in Culture
Letters in Drug Design & Discovery Regulation of p53 Activity
Current Chemical Biology In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Current Drug Targets Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Higher Placental Anti-Inflammatory IL-10 Cytokine Expression in HIV-1 Infected Women Receiving Longer Zidovudine Prophylaxis Associated with Nevirapine
Current HIV Research Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
Current Radiopharmaceuticals Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Multiple Sclerosis
Current Medicinal Chemistry New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy
Current Cancer Drug Targets NQDI 1, An Inhibitor of ASK1 Attenuates Acute Ischemic Renal Injury by Modulating Oxidative Stress and Cell Death
Cardiovascular & Hematological Agents in Medicinal Chemistry In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry